NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer
Agenus presented Phase II NEOASIS study results at ESMO 2026, showing 83% pathological response rate in dMMR colorectal cancer patients treated with neoadjuvant botensilimab plus balstilimab. 72% achieved complete response. Safety profile included Grade 1-2 immune-related adverse events in 72% of patients, with one Grade 3 colitis case. The study met its primary endpoint, supporting further evaluation.
How this was made
The 30-second read
Why it matters
The high major pathological response rate (83%) and 72% complete responses suggest a promising neoadjuvant regimen, likely prompting analyst upgrades and short‑term buying interest.
Market read
First public disclosure of Phase II efficacy data for a novel neoadjuvant immunotherapy, a material catalyst for the stock.
What to watch
Potential safety concerns with Grade 3 colitis and ileus could temper enthusiasm
Background
Agenus (NASDAQ: AGEN) disclosed early clinical data at the European Society for Medical Oncology (ESMO) 2026 Congress.
Ticker impact
Agenus presented Phase II NEOASIS data showing 83% major pathological response in dMMR colorectal cancer.
likely upward pressure as investors price in strong efficacy signals
Phase II data with high response rates is material for a biotech; market typically reacts positively to such early‑stage success.
Market effects
strengthens outlook for immunotherapy in dMMR colorectal cancer and may benefit peers in checkpoint inhibitor space
European biotech investors may see increased interest following ESMO presentation
adds to global pipeline momentum for checkpoint blockade therapies
Counterpoint
Data is from a small Phase II cohort; efficacy may not translate to larger trials, risk of overvaluation
Key entities
- companyAgenus
Biopharma developing checkpoint inhibitor antibodies botensilimab and balstilimab.
- personEmma van den Berg
Presenter of the NEOASIS results at ESMO.
